Curated by the JDD Editors
Missed any of our October highlights? October is our Atopic Dermatitis focused issue–start to dive in! Catch up with this curated roundup from the JDD Editors—your guide to must-read articles for the derm community.
In Memoriam: Ronald Moy MD (1957–2025)
SAIGE I: Staphylococcus aureus, Immunological, Genetic, and Environmental (SAIGE) Factors Contributing to Atopic Dermatitis and the Use of Ceramide-Containing Skincare evaluates the risk of subcutaneous nodules and lipoma development in the upper arm after intramuscular influenza vaccination.
1% Colloidal Oatmeal Cream/Baby Wash Regimen Improved Atopic Dermatitis in Pediatric Patients From First Use supports the efficacy and safety/tolerability of the study regimen in infants/children with predominantly mild AD.
An Exosome Regenerative Complex Plus Microneedling Promotes Hair Growth in Subjects With Self-Perceived Thinning Hair explores how procedures on the scalp can significantly increase terminal and vellus hair counts and decreased hair shedding.
Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months suggests a substantial proportion of patients with AD have unaddressed treatment needs.
Skin Barrier Benefits of a Natural Moisturizing Factors and Lipid-Based Moisturizer for Clinically Sensitive Skin evaluates its biological effects on critical epidermal proteins, lipids, genes, and clinical improvements in skin barrier strength and tolerability.
Ruxolitinib Cream vs Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis compares their uses in this phase 2 study and shares the outcomes.
Increased Risk of Subcutaneous Nodules and Lipomas Following Influenza Vaccination: A Multicenter TriNetX Cohort Study evaluates the risk of subcutaneous nodules and lipoma development in the upper arm.
The Role of Simultaneous Janus Kinase Inhibitor and Biologic Therapy Use for Refractory Atopic Dermatitis highlights the safety and efficacy of biologic and JAKi therapy for AD refractory to monotherapy treatments.
Refractory Pruritus Secondary to Linear IgA Bullous Dermatosis Treated Successfully With Nemolizumab: A Case Report summarizes how this treatment resolved a patient’s itch discomfort.
